论文部分内容阅读
目的:探讨以氯法齐明为主药方案治疗广泛耐多药肺结核的临床效果。方法:采用含氯法齐明、克拉霉素、阿莫西林克拉维酸钾、卷曲霉素、丙硫异烟胺抗结核方案治疗45例涂阳、广泛耐多药肺结核患者,观察治疗2,4,6,12个月即疗程结束时痰菌阴转率,病灶吸收率。结果:治疗2,4,6,12个月有效率分别为80.3%,86.7%,95.6%,95.6%;痰菌阴转率分别为42.2%,77.8%,84.4%,86.7%,病灶吸收率分别为71.1%,82.2%,88.9%,91.1%。结论:以氯法齐明为主药方案治疗广泛耐多药肺结核效果满意。
Objective: To investigate the clinical efficacy of clofazimine as the main drug in the treatment of MDR-TB. Methods: Forty-five patients with smear-positive and broad-spectrum multidrug-resistant pulmonary tuberculosis were treated with chlorine-containing ramizamil, clarithromycin, amoxicillin and clavulanate, capreomycin, and propylthiouracil. 4,6,12 months that the end of treatment when sputum negative conversion rate, the rate of absorption of the lesion. Results: The effective rates were 80.3%, 86.7%, 95.6% and 95.6% respectively at the 2nd, 4th, 6th and 12th month after treatment. The sputum negative conversion rates were 42.2%, 77.8%, 84.4% and 86.7% Respectively 71.1%, 82.2%, 88.9%, 91.1%. Conclusion: The efficacy of clofazimine-based drug in the treatment of MDR-TB is satisfactory.